Lori Kunkel

Dr. Kunkel has more than 20 years of experience in oncology and immunology drug development and commercialization. From October 2013 to October 2014, she was the acting Chief Medical Officer of Loxo Oncology, Inc. Prior to that, she was Chief Medical Officer of Pharmacyclics LLC, which was acquired by AbbVie, and Chief Medical Officer of Proteolix, Inc., which was acquired by Onyx Pharmaceuticals. Prior to those positions, she held various senior clinical roles at Baxter Healthcare, Chiron Corp, Genentech, Inc. and Xencor, Inc. Additionally, as a clinical drug development specialist, Dr. Kunkel has advised multiple clients including Atreca, Enliven Therapeutics, Elevation Oncopeptides, Oryzon Genomics and Rain Therapeutics. Prior to joining the biotechnology industry, Dr. Kunkel spent 10 years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. She currently serves on the board of directors of Curis Inc, Maverick Therapeutics, Oric Pharma and Nurix Therapeutics and previously served on the board of directors of Loxo Oncology, Amphivena, Harpoon Therapeutics and Tocagen. Dr. Kunkel received a medical degree from the University of Southern California and a bachelor’s degree in biology from the University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.